Funding for this research was provided by:
Health Technology Assessment Programme (15/57/66)
Received: 9 January 2021
Accepted: 14 June 2021
First Online: 1 July 2021
: The trial is being performed in accordance with the World Medical Association Declaration of Helsinki and UK ethical approval has been granted by the National Research Ethics Service (reference: CitationRef removed/EM/0440). Each participating site is required to approve the trial via a site-specific assessor prior to entering participants into the trial. All participants are required to provide informed written consent to participate.
: Not applicable.
: PC has received speaker fees and sat on advisory boards for MSD, BMS, Novartis and Pierre Fabre. RP has received conference and travel support from MSD and BMS; and sat on advisory boards or received speaker fees from BMS, Pierre Faber and Novartis. FG has consulted for AstraZeneca and has research funding from GSK. SR is CEO of charity Melanoma Focus. SD has received conference and travel support from MSD, Pierre Fabre and BMS; and sat on advisory boards for MSD and BMS. The remaining authors declare no competing interests.